Clinical Outcomes of Oral Suspension versus Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections

Posaconazole is used for prophylaxis for invasive fungal infections (IFIs) among patients with hematologic malignancies. We compared the incidence of breakthrough IFIs and early discontinuation between patients receiving delayed-release tablet and oral suspension formulations of posaconazole. This w...

Descripción completa

Detalles Bibliográficos
Autores principales: Furuno, Jon P., Tallman, Gregory B., Noble, Brie N., Bubalo, Joseph S., Forrest, Graeme N., Lewis, James S., Bienvenida, Ana F., Holmes, Courtney A., Weber, Bo R., McGregor, Jessina C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2018
Materias:
Clinical Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6153813/
https://www.ncbi.nlm.nih.gov/pubmed/30012757
http://dx.doi.org/10.1128/AAC.00893-18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6153813/
https://www.ncbi.nlm.nih.gov/pubmed/30012757
http://dx.doi.org/10.1128/AAC.00893-18

Ejemplares similares